US Physical Therapy Analyst Price Targets

Wall Street analyst price targets and consensus rating for US Physical Therapy (USPH).

Price Target Range — 12 Quarters

Analyst Consensus — 6 Analysts

2S.Buy

4Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$104Upside to Avg. PT+17.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 11, 2026	JP Morgan	Benjamin Rossi	PT Raise	Overweight	$90→$95
Aug 10, 2026	Barrington Research	Michael Petusky	PT Raise	Outperform	$90→$98
Jun 24, 2026	Citizens	Constantine Davides	Maintained	Market Outperform	$98
May 13, 2026	Barrington Research	Michael Petusky	PT Cut	Outperform	$103→$90
May 8, 2026	Citizens	Constantine Davides	PT Cut	Market Outperform	$113→$98
Mar 10, 2026	Jefferies	Brian Tanquilut	Assumes	Buy	$102
Feb 20, 2026	Barrington Research	Michael Petusky	Maintained	Outperform	$103
Jan 5, 2026	Barrington Research	Michael Petusky	Maintained	Outperform	$103
Nov 24, 2025	JP Morgan	Benjamin Rossi	PT Cut	Overweight	$110→$100
Oct 24, 2025	Barrington Research	Michael Petusky	Maintained	Outperform	$103
Sep 18, 2025	JP Morgan	Benjamin Rossi	Assumes	Overweight	$110
Aug 8, 2025	Barrington Research	Michael Petusky	PT Raise	Outperform	$98→$103
Jul 1, 2025	Barrington Research	Michael Petusky	Maintained	Outperform	$98
Apr 22, 2025	JMP Securities	Constantine Davides	Maintained	Market Outperform	$113
Mar 19, 2025	JP Morgan	Calvin Sternick	PT Cut	Overweight	$120→$110
Feb 28, 2025	Barrington Research	Michael Petusky	PT Cut	Outperform	$108→$98
Dec 16, 2024	B of A Securities	Joanna Gajuk	Upgrade	Neutral→Buy	$100→$115
Dec 16, 2024	JMP Securities	Constantine Davides	Initiate	Market Outperform	$113
Dec 3, 2024	JP Morgan	Calvin Sternick	PT Raise	Overweight	$117→$120
Nov 21, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$108

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on US Physical Therapy, Raises Price Target to $95

JP Morgan analyst Benjamin Rossi maintains US Physical Therapy (NYSE:USPH) with a Overweight and raises the price target from $90 to $95.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $98

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:USPH) with a Outperform and raises the price target from $90 to $98.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on US Physical Therapy, Maintains $98 Price Target

Citizens analyst Constantine Davides reiterates US Physical Therapy (NYSE:USPH) with a Market Outperform and maintains $98 price target.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Lowers Price Target to $90

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:USPH) with a Outperform and lowers the price target from $103 to $90.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on US Physical Therapy, Lowers Price Target to $98

Citizens analyst Constantine Davides maintains US Physical Therapy (NYSE:USPH) with a Market Outperform and lowers the price target from $113 to $98.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Maintains $103 Price Target

Barrington Research analyst Michael Petusky maintains US Physical Therapy (NYSE:USPH) with a Outperform and maintains $103 price target.

Benzinga Newsdesk

US Physical Therapy Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

US Physical Therapy Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on US Physical Therapy, Raises Price Target to $95

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $98

PRO
Citizens Reiterates Market Outperform on US Physical Therapy, Maintains $98 Price Target

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Lowers Price Target to $90

PRO
Citizens Maintains Market Outperform on US Physical Therapy, Lowers Price Target to $98

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Maintains $103 Price Target

People Also Watch

People Also Watch

US Physical Therapy Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

US Physical Therapy Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on US Physical Therapy, Raises Price Target to $95

PROBarrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $98

PROCitizens Reiterates Market Outperform on US Physical Therapy, Maintains $98 Price Target

PROBarrington Research Maintains Outperform on US Physical Therapy, Lowers Price Target to $90

PROCitizens Maintains Market Outperform on US Physical Therapy, Lowers Price Target to $98

PROBarrington Research Maintains Outperform on US Physical Therapy, Maintains $103 Price Target

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on US Physical Therapy, Raises Price Target to $95

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $98

PRO
Citizens Reiterates Market Outperform on US Physical Therapy, Maintains $98 Price Target

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Lowers Price Target to $90

PRO
Citizens Maintains Market Outperform on US Physical Therapy, Lowers Price Target to $98

PRO
Barrington Research Maintains Outperform on US Physical Therapy, Maintains $103 Price Target